Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Astellas Upwardly Revises Business Forecasts Driven by Vesicare
October 31, 2011
- Abilify Posted US Sales of US$983 Mil. in Jul-Sep
October 31, 2011
- Anti-HIV JTK-303 Applied for Combination Tablet in the US: JT
October 31, 2011
- Losses Increase Due to Fallen Milestone Payments: OncoTherapy
October 31, 2011
- Wakamoto’s Apr-Sep Profits Up 2% on Latanoprost Sales Growth, Recovered Losses
October 31, 2011
- Terumo Posts Record Sales, Operating Profits in First Half FY2012
October 31, 2011
- PI Trial of Darinaparsin Inj. Starts for PTCL: Solasia
October 31, 2011
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
- Meiji Seika Pharma Planning to Develop Biosimilars for Infectious Diseases, Cancer, and RA
October 31, 2011
- Medipal HD: Near 90% Decline in Operating Profits
October 31, 2011
- Kyowa Kirin’s Pharmaceutical Business Reports Increases in Sales, Profits in Jan.-Sept. Driven by Nesp
October 28, 2011
- Novartis to Cut 2,000 Jobs in Manufacturing, Development Division
October 28, 2011
- Hisamitsu Forms Chinese Subsidiary to Enter OTC Business
October 28, 2011
- JDF, Eli Lilly Japan Create Subsidy Program for Basic Incretin Research
October 28, 2011
- Nitto Denko, Maruho Apply for Additional Indication for Penles Tape for Pain Relief with Removal of Warts
October 28, 2011
- Bayer to Continue to Discuss Filing for Approval for Regorafenib in Europe, US after Improvement of OS in PIII Trial
October 28, 2011
- Baxter's Worldwide Sales Up 10% to US$10.3 Bil. for 1st Nine Months of 2011
October 28, 2011
- Terumo: Record Sales, Operating Profits in 1st Half of FY2011
October 28, 2011
- Nexium Tops HP Market in September Led by 2 Active Marketers: RepTrack Survey
October 27, 2011
- DSP to Distribute iPad2 to All MRs from Jan. Next Year
October 27, 2011
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…